Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation

Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GYH, Kuramatsu J, Huttner H, Fang J, Schulman S, Marti-Fabregas J, Gathier CS, Viswanathan A, Biffi A, Poli D, Weimar C, Malzahn U, Heuschmann P, Veltkamp R (2017)


Publication Type: Journal article

Publication year: 2017

Journal

Book Volume: 89

Pages Range: 687-696

Journal Issue: 7

DOI: 10.1212/WNL.0000000000004235

Abstract

To perform a systematic review and meta-analysis of studies reporting recurrent intracranial hemorrhage (ICH) and ischemic stroke (IS) in ICH survivors with atrial fibrillation (AF) during long-term follow-up.A comprehensive literature search including MEDLINE, EMBASE, Cochrane library, clinical trials registry was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We considered studies capturing outcome events (ICH recurrence and IS) for >=3 months and treatment exposure to vitamin K antagonists (VKAs), antiplatelet agents (APAs), or no antithrombotic medication (no-ATM). Corresponding authors provided aggregate data for IS and ICH recurrence rate between 6 weeks after the event and 1 year of follow-up for each treatment exposure. Meta-analyses of pooled rate ratios (RRs) were conducted with the inverse variance method.Seventeen articles met inclusion criteria. Seven observational studies enrolling 2,452 patients were included in the meta-analysis. Pooled RR estimates for IS were lower for VKAs compared to APAs (RR = 0.45, 95% confidence interval [CI] 0.27-0.74, p = 0.002) and no-ATM (RR = 0.47, 95% CI 0.29-0.77, p = 0.002). Pooled RR estimates for ICH recurrence were not significantly increased across treatment groups (VKA vs APA: RR = 1.34, 95% CI 0.79-2.30, p = 0.28; VKA vs no-ATM: RR = 0.93, 95% CI 0.45-1.90, p = 0.84).In observational studies, anticoagulation with VKA is associated with a lower rate of IS than APA or no-ATM without increasing ICH recurrence significantly. A randomized controlled trial is needed to determine the net clinical benefit of anticoagulation in ICH survivors with AF.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Korompoki, E., Filippidis, F.T., Nielsen, P.B., Del Giudice, A., Lip, G.Y.H., Kuramatsu, J.,... Veltkamp, R. (2017). Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology, 89(7), 687-696. https://dx.doi.org/10.1212/WNL.0000000000004235

MLA:

Korompoki, Eleni, et al. "Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation." Neurology 89.7 (2017): 687-696.

BibTeX: Download